Pharmalot (Free subscription) | yesterday
Heinz-Werner Meier, who runs the drugmaker’s German operations, will leave his post at the end of the year, Financial Times Deutschland reported. Meier, a long-time executive at German drugs and chemicals maker Hoechst, which is now part of Sanofi-Aventis, will also resign from his role as the worldwide head of human resources on September 1. [...]
Japan Times (Free subscription) | 07/22/2008
Chugai Pharmaceutical Co., the Japanese unit of Roche Holding AG, said Tuesday its first-half profit fell 10 percent on lower sales of the antiviral drug Tamiflu and after the company ended a partnership with Sanofi-Aventis SA. Net profit dropped to about ¥18.9 billion from ¥21.1 billion a year earlier, Chugai Pharma said in a statement to the Tokyo Stock Exchange. The result exceeded an April forecast...
The Earth Times Online Newspaper (Free subscription) | 07/22/2008
Prague - Czech financial group PPF said Tuesday it plans to withdraw its takeover offer for Czech generics drug maker Zentiva, pulling out from a bidding war with French pharmaceutical group Sanofi-Aventis. The reasons for our step lie in reasonable...
Medical News Today (Free subscription) | 07/22/2008
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the agreement announced by Clinton Foundation HIV/AIDS Initiative (CHAI) to reduce the volatility and the price levels of Artemisinin-based Combination Therapies (ACT).
New York Times (Free subscription) | 07/22/2008
The French pharmaceuticals maker agreed to buy Primary Health Care, the biggest distributor of vitamin supplements in Australia, for 560 million Australian dollars ($546 million).
Red Orbit (Free subscription) | 07/21/2008
Sanofi-Aventis has announced that it is returning its territory rights to Japan-based Taiho Pharmaceutical for the development and commercialization of the oral anticancer agent S-1.
Red Orbit (Free subscription) | 07/21/2008
Sanofi-Aventis has signed a three year agreement with the division of allergy and clinical immunology of the Johns Hopkins University School of Medicine, Baltimore, Maryland.
New Zealand Herald (Free subscription) | 07/21/2008
SYDNEY - Primary Health Care will sell the consumer business of Symbion Health, which it took over this year, to Sanofi-aventis for A$560 million ($717 million). The agreement to sell the business to the French group's Australian...
Forbes (Free subscription) | 07/21/2008
The Australian operator of medical clinics decides that the pills business it acquired with Symbion Health is not a fit, so it is selling it on to Sanofi-Aventis for $546.6 million.
Law Blog - WSJ.com (Free subscription) | 07/21/2008
Australia's Primary Health Care agreed to sell its vitamin-making unit to French drug maker Sanofi-Aventis for $543.4 million.
Financial Time (Free subscription) | 07/21/2008
The French drugmaker agreed to acquire Primary Health's consumer business for A$560m, allowing the group to deepen its presence in the Australian healthcare sector
Market Watch (Free subscription) | 07/21/2008
LONDON (MarketWatch) -- Sanofi-Aventis said it's going to pay Symbion CP Holdings from Primary Health Care for A$560 million ($545 million). Symbion is the market leader in Australia in selling vitamins and mineral supplements. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BBC News (Free subscription) | 07/21/2008
French drugs giant Sanofi-Aventis is to buy Australia's largest distributor of vitamin supplements.
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/21/2008
MELBOURNE (Reuters) - French drug maker Sanofi-Aventis (SASY.PA: ) has agreed to pay A$560 million ($544 million) to Primary Health Care Ltd (PRY.AX: ) ...
Business Spectator (Free subscription) | 07/21/2008
Health services firm will sell vitamin business to pay down debt. 21 Jul 2008 8:21 AM
The last article published by a user on Sanofi-Aventis :
nitesh | 05/31/2008
The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% market share. However, in 2006 Ambien loses its patent protection, and the sleep disorder market looks set for dramatic growth and the introduction of at least four new products. In April 2005 year the first...
